NPT-2042 is under clinical development by NeuroPro Therapeutics and currently in Phase I for Seizures. According to GlobalData, Phase I drugs for Seizures have a 92% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NPT-2042’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NPT-2042 overview

NPT-2042 is under development as an adjunct anti seizure treatment for patients with medically intractable epilepsy. It is administered as soft-gelatin capsules administered through orally route.

NeuroPro Therapeutics overview

NeuroPro Therapeutics is a North Carolina-based stealth biotechnology company. NeuroPro Therapeutics is headquartered in Bahama, North Carolina, the US.

For a complete picture of NPT-2042’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.